ACTRN12624000039583尚未招募4 期
Evaluating the effect of Dapagliflozin on Alanine Transaminase Levels in Type 2 Diabetic Patients with Non Alcoholic Fatty Liver Disease
MTI Lady Reading Hospital0 个研究点目标入组 192 人开始时间: 2024年1月17日最近更新:
适应症
试验速览
- 阶段
- 4 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 192
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 16 Years 至 75 Years（—）
- 性别
- All
入选标准
- •1. Age 16 years or older.
- •2.Gender: Any
- •3.Patients already diagnosed as having type 2 diabetes mellitus (Fasting blood glucose of >126 mg/dl or HbA1C > 6.5 %) , having suboptimal glycemic control (HbA1C > 7%) on current treatment who are having Alanine Transaminase (ALT)levels > 40IU/L and ultrasonographical features of Non Alcoholic Fatty Liver Disease (NAFLD).
排除标准
- •1.Patients with type 1 diabetes mellitus (Sodium-Glucose Co Transporter 2 (SGLT2) inhibitors (SGLT2 inhibitors may precipitate Diabetic Ketoacidosis)
- •2. Pregnancy (SGLT2 inhibitors not licensed).
- •3.Patients already on SGLT2 inhibitors
- •4.Patients having impaired renal function (estimated Glomerular Filtration rate of < 45ml/min/1.73m2),
- •5.Patients having chronic liver disease, positive viral serology for hepatitis B and C, history of alcohol consumption, having clinical features of hyperthyroidism, recent infections, history of cancer and evidence of gall-stones/cholecystitis on ultrasound,
- •6.Patients having recent (within 6 months) acute coronary syndrome
- •7. Cancer of any sort.
研究者
相似试验
进行中（未招募）
1 期
This study is designed to test the hypothesis that the treatment-induced reductions in the ambulatory aortic pressure are more pronounced in the group of dapagliflozin than in the group of placebo (benefit/risk and ethical assessment) and its effects on arterial stiffness and urine albumin excretion in patients with type 2 diabetes.MedDRA version: 18.1Level: LLTClassification code 10029505Term: Non-insulin-dependent diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersA study of the effects of dapagliflozin on ambulatory aortic pressure, arterial stiffness and urine albumin excretion in patients with type 2 diabetes mellitus.MedDRA version: 18.1Level: SOCClassification code 10027433Term: Metabolism and nutrition disordersSystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2015-005288-17-GR???????? ???????? ???????S ????????S?S (Hellenic Society of Medical Education)160
进行中（未招募）
1 期
Study to evaluate if dapagliflozin treatment is effective in patients with heart failure by reducing the number of hospitalizations and urgent visits due to heart failure, and by reducing the risk of death.Chronic Heart Failure (HF) with Reduced Ejection FractionEUCTR2016-003897-41-PLAstraZeneca AB4,500
进行中（未招募）
1 期
Study to evaluate if dapagliflozin treatment is effective in patients with heart failure by reducing the number of hospitalizations and urgent visits due to heart failure, and by reducing the risk of death.Chronic Heart Failure (HF) with Reduced Ejection FractionMedDRA version: 20.0 Level: PT Classification code 10007558 Term: Cardiac failure chronic System Organ Class: 10007541 - Cardiac disordersEUCTR2016-003897-41-DKAstraZeneca AB4,500
进行中（未招募）
1 期
Study to evaluate if dapagliflozin treatment is effective in patients with heart failure by reducing the number of hospitalizations and urgent visits due to heart failure, and by reducing the risk of death.Chronic Heart Failure (HF) with Reduced Ejection FractionEUCTR2016-003897-41-BGAstraZeneca AB4,500
已完成
3 期
DAPA-HFChronic Heart Failure With Reduced Ejection Fraction (HFrEF)JPRN-jRCT2080223469AstraZeneca KK330